Sanofi (SAN):企業の財務・戦略的SWOT分析

◆英語タイトル:Sanofi (SAN) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH3811FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:97
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Sanofi (SAN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sanofi is a healthcare company which discovers, develops, manufactures and markets a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi’s R&D efforts focus on advancing combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce medicines with precision. It has operations across Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

Sanofi Key Recent Developments

Apr 07,2021: Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
Mar 03,2021: Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
Feb 22,2021: Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
Feb 05,2021: Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
Feb 05,2021: Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Sanofi – Key Facts
Sanofi – Key Employees
Sanofi – Key Employee Biographies
Sanofi – Major Products and Services
Sanofi – History
Sanofi – Company Statement
Sanofi – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
Sanofi – Business Description
Business Segment: Consumer Health
Overview
Performance
Business Segment: Pharmaceuticals
Overview
Performance
Business Segment: Vaccines
Overview
Performance
Geographical Segment: Europe
Target Markets
Performance
Geographical Segment: Rest of the World
Target Markets
Performance
Geographical Segment: United States
Performance
R&D Overview
Sanofi – Corporate Strategy
Sanofi – SWOT Analysis
SWOT Analysis – Overview
Sanofi – Strengths
Sanofi – Weaknesses
Sanofi – Opportunities
Sanofi – Threats
Sanofi – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sanofi, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 07, 2021: Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
Mar 03, 2021: Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
Feb 22, 2021: Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
Feb 05, 2021: Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
Feb 05, 2021: Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
Jan 25, 2021: Curadigm, a subsidiary of Nanobiotix, signs a collaboration agreement with Sanofi focused on the gene therapy portfolio
Jan 25, 2021: Orange, Sanofi, Capgemini and Generali Plans to Form Joint Venture
Jan 22, 2021: Ten leading bioPharma companies announce formation of Accumulus Synergy to develop global data sharing platform
Jan 14, 2021: Kiadis draws €20 million from bridge loan with Sanofi
Jan 12, 2021: SANOFI unveils EUROAPI as the name of the new industry leading European API company and appoints Karl Rotthier as its future chief executive officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Sanofi, Key Facts
Sanofi, Key Employees
Sanofi, Key Employee Biographies
Sanofi, Major Products and Services
Sanofi, History
Sanofi, Subsidiaries
Sanofi, Joint Venture
Sanofi, Key Competitors
Sanofi, Ratios based on current share price
Sanofi, Annual Ratios
Sanofi, Annual Ratios (Cont...1)
Sanofi, Annual Ratios (Cont...2)
Sanofi, Interim Ratios
Sanofi, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Sanofi, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Sanofi, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Sanofi (SAN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Progenitor Cell Therapy LLC-製薬・医療分野:企業M&A・提携分析
    Summary Progenitor Cell Therapy LLC (PCT), a subsidiary of Caladrius Biosciences Inc is an external development and manufacturing company that offers cell therapy products. The company offers services that include cell and tissue processing; storage, distribution and delivery; consulting and regulat …
  • Genomic Health Inc (GHDX)-医療機器分野:企業M&A・提携分析
    Summary Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The company’s commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer …
  • Visterra Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Visterra Inc (Visterra), formerly Parasol Therapeutics Inc is a clinical-stage biopharmaceutical company that develops antibody therapies for the treatment of infectious diseases. The company develops precision antibody-based biological medicines for infectious and non-infectious diseases. I …
  • BARMER GEK:企業の戦略的SWOT分析
    BARMER GEK - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Neovasc Inc (NVCN):医療機器:M&Aディール及び事業提携情報
    Summary Neovasc Inc (Neovasc) is a medical device manufacturing company that manufactures, develops, and sells cardiovascular disease products. The company’s products include Neovasc reducer, Neovasc tiara, and Neovasc tissue products. Its Neovasc tiara is a novel transcatheter device that is design …
  • Xeltis AG:企業の製品パイプライン分析2018
    Summary Xeltis AG (Xeltis) is a clinical-stage medical equipment company that harnesses advances in science to improve the treatment of heart valve related conditions. The company’s polymer-based technology platform, RestoreX, facilitates the natural restoration of heart valve through a process refe …
  • Fitbit Inc.:戦略・SWOT・企業財務分析
    Fitbit Inc. - Strategy, SWOT and Corporate Finance Report Summary Fitbit Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Coats Group plc:企業のM&A・事業提携・投資動向
    Coats Group plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Coats Group plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Shionogi & Co., Ltd.:企業の戦略・SWOT・財務分析
    Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • The Nisshin OilliO Group Ltd (2602):企業の財務・戦略的SWOT分析
    The Nisshin OilliO Group Ltd (2602) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Ypsomed Holding AG (YPSN)-医療機器分野:企業M&A・提携分析
    Summary Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops and manufactures injection systems. Its offers pen injectors, autoinjectors, dual chamber pens and other custom products. The company also offers contract manufacturing, industrial design, human factors engineerin …
  • Memry Corp:企業の戦略的SWOT分析
    Memry Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Molecular Templates Inc:企業のM&A・事業提携・投資動向
    Molecular Templates Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Molecular Templates Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • PartnerRe Ltd.:企業のM&A・事業提携・投資動向
    PartnerRe Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's PartnerRe Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • CALBEE, Inc. (2229):企業の財務・戦略的SWOT分析
    CALBEE, Inc. (2229) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Isovolta AG:企業の戦略的SWOT分析
    Isovolta AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Cheil Worldwide Inc. (030000):企業の財務・戦略的SWOT分析
    Cheil Worldwide Inc. (030000) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Royal KPN N.V.:企業の戦略・SWOT・財務情報
    Royal KPN N.V. - Strategy, SWOT and Corporate Finance Report Summary Royal KPN N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Temple Hotels Inc.
    Temple Hotels Inc. - Strategy, SWOT and Corporate Finance Report Summary Temple Hotels Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Questerre Energy Corp (QEC):企業の財務・戦略的SWOT分析
    Summary Questerre Energy Corp (Questerre) is an independent oil and gas exploration and development company that acquires, explores, develops and produces unconventional oil and gas properties. The company’s unconventional properties include tight oil, shale oil and shale gas. It has base production …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆